Table 2.
Optimal background anti-TB drugs used in patients with MDR/XDR-TB with or without DM
| Drugs, no. (%) | DM group (n = 107) | Non-DM group (n = 107) | P value |
|---|---|---|---|
| Moxifloxacin | 51 (47.7) | 59 (55.1) | 0.274 |
| Levofloxacin | 10 (9.3) | 11 (10.3) | 0.818 |
| Linezolid | 97 (90.7) | 96 (89.7) | 0.818 |
| Clofazimine | 77 (72.0) | 69 (64.5) | 0.240 |
| Cycloserine | 91 (85.0) | 89 (83.2) | 0.708 |
| Ethambutol | 12 (11.2) | 9 (8.4) | 0.491 |
| Pyrazinamide | 24 (22.4) | 19 (17.8) | 0.394 |
| Protionamide | 49 (45.8) | 55 (51.4) | 0.412 |
| Amikacin | 31 (29.0) | 42 (39.3) | 0.113 |
| Capreomycin | 22 (20.6) | 25 (23.4) | 0.620 |
| p-Aminosalicylic acid | 43 (40.2) | 33 (30.8) | 0.153 |
| Pasiniazid | 2 (1.9) | 2 (1.9) | > 0.999 |
| Amoxicillin/clavulanic acid | 12 (11.2) | 11 (10.3) | 0.825 |
| Streptomycin | 1 (0.9) | 0 (0) | > 0.999 |
| Clarithromycin | 3 (2.8) | 0 (0) | 0.246 |
| High-dose isoniazid | 2 (1.9) | 1 (0.93) | > 0.999 |
| Median no. of drugs in background regimen, (IQR) | 5 (4–5) | 5 (4–5) | 0.364 |